Quarterly ResultMay 5, 2026, 04:08 PM
Standard BioTools Q1 Revenue $21.1M; Adj EBITDA Loss $3.1M, up 78%
AI Summary
Standard BioTools Inc. announced strong first quarter 2026 financial results, with revenue reaching $21.1 million, a 5% increase year-over-year. The company significantly reduced its operating loss by 54% and improved adjusted EBITDA by 78% year-over-year to a loss of $3.1 million, reinforcing its path to profitability. With approximately $550 million in cash and investments, the company is focused on strategic capital deployment for inorganic growth following the completion of the SomaLogic sale.
Key Highlights
- Q1 2026 revenue was $21.1 million, up 5% year-over-year.
- Adjusted EBITDA improved 78% year-over-year to a loss of $3.1 million.
- Operating loss reduced by 54% year-over-year to $12.5 million.
- Cash and investments totaled approximately $550 million as of March 31, 2026.
- Consumables revenue grew 35% year-over-year to $11.0 million.
- Instruments revenue decreased 33% year-over-year to $4.5 million.
- Net loss from continuing operations improved 37% to $14.6 million.
- Full year 2026 revenue outlook remains $80 million to $85 million.